Behind generic drug shortages, House committee points to lackluster manufacturing and high prices

The see­saw be­tween ques­tion­able gener­ic drug man­u­fac­tur­ing and rock bot­tom prices took the spot­light at a House Ways and Means Com­mit­tee hear­ing on chron­ic drug short­ages Tues­day morn­ing.

“Poor man­u­fac­tur­ing qual­i­ty is the lead­ing dri­ver of chron­ic short­ages and it’s the most pre­ventable,” Com­mit­tee Chair Ja­son Smith (R-MO) said at the start of the hear­ing. The com­mit­tee turned to six ex­perts from in­dus­try and acad­e­mia to un­der­stand po­ten­tial so­lu­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.